Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2025/140489MULTISPECIFIC ANTIBODIES AND USES THEREOF
WO 03.07.2025
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/CN2024/142997 Applicant VIBRANT PHARMA LIMITED Inventor WANG, Luquan
Provided are multispecific antibodies (e.g., bispecific antibodies or trispecific antibodies) or antigen-binding fragments thereof. In one aspect, the multispecific antibodies or antigen-binding fragments thereof can bind to a T cell antigen (e.g., CD3) and/or one or two tumor-associated antigens (e.g., CAIX, EGFR), or a combination thereof.
2.WO/2025/140654ANTI-CDH17 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE THEREOF
WO 03.07.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2024/143461 Applicant GUANGDONG FAPON BIOPHARMA INC. Inventor ZHANG, Yibo
An anti-CDH17 antibody or an antigen-binding fragment thereof and the use thereof. The antibody can specifically bind to one or more extracellular domains in extracellular domains 1-7 of CDH17, has an ADCC activity, and can mediate cell endocytosis, thereby providing a new possibility for the treatment and/or prevention of cancers.
3.WO/2025/140324USE OF ANTI-PD-1 ANTIBODY COMBINED WITH CHEMOTHERAPEUTIC AGENT IN TREATMENT OF TUMORS
WO 03.07.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2024/142361 Applicant BIO-THERA SOLUTIONS, LTD. Inventor WANG, Hao
Provided is a use of an anti-PD-1 antibody combined with a chemotherapeutic agent in the treatment of tumors such as cervical cancer or endometrial cancer. In some embodiments, the chemotherapeutic agent comprises a taxane drug and/or a platinum drug. In some embodiments, the use further comprises a use of the anti-PD-1 antibody combined with bevacizumab.
4.WO/2025/143714DIAGNOSTIC KIT FOR BOVINE DIARRHEA-CAUSING VIRUS
WO 03.07.2025
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No PCT/KR2024/020949 Applicant BOREDA BIOTECH Inventor CHOI, Dong Ok
The present invention relates to a diagnostic kit for bovine viral diarrhea virus (BVDV), which enables rapid on-site identification and diagnosis of BVDV1 and BVDV2, which are genotypes of the BVD virus that are pathogens causing bovine diarrhea, within a short time of approximately 15 minutes.
5.WO/2025/144089MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO TL1A
WO 03.07.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/RU2024/050327 Applicant JOINT STOCK COMPANY "BIOCAD" Inventor NISKANEN, Sergei Andreevich
The present invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to TNF-like ligand 1A (TL1A). The invention further relates to nucleic acids encoding said antibody, expression vectors, host cells and methods for producing same, methods for producing the antibodies according to the invention, pharmaceutical compositions comprising the antibody or antigen-binding fragment thereof according to the invention, as well as to pharmaceutical compositions comprising the antibody or antigen-binding fragment thereof according to the invention and other therapeutically active compounds; to methods for treating TL1A-mediated diseases or disorders, to use of the antibody or antigen-binding fragment thereof or pharmaceutical composition thereof for treating TL1A-mediated diseases or disorders, and to use of the antibody or antigen-binding fragment thereof according to the invention and other therapeutically active compounds for treating TL1A-mediated diseases or disorders.
6.WO/2025/145064INTERLEUKIN 18 (IL-18) VARIANTS AND FUSION PROTEINS COMPRISING SAME
WO 03.07.2025
Int.Class C07K 16/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
Appl.No PCT/US2024/062128 Applicant SONNET BIOTHERAPEUTICS, INC. Inventor CINI, John K.
Provided herein are variant human IL-18 (hIL-18) proteins and fusion proteins comprising the variant hIL-18 proteins. Such variant hIL-18 proteins exhibit biological IL-18 activity while having reduced or no detectable binding to inhibitory IL-18BP. Thus, in some embodiments, the variant hIL-18 proteins advantageously retain IL-18 biological activity in the presence of IL-18BP. Such variant hIL-18 and related fusion proteins find use, for example, in the treatment of cancer.
7.WO/2025/140535PD-1/IL-2R BISPECIFIC ANTIBODY FUSION PROTEIN, AND USE AND USAGE METHOD THEREOF
WO 03.07.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2024/143132 Applicant FORTVITA BIOLOGICS (SINGAPORE) PTE. LTD. Inventor ZHOU, Hui
The present invention relates to a PD-1/IL-2R bispecific antibody fusion protein for treating tumors (such as solid tumors or hematologic tumors), or a pharmaceutical composition or pharmaceutical combination containing same, and a use and usage method thereof.
8.WO/2025/140010ANTI-CD3 ANTIBODY AND USE THEREOF
WO 03.07.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2024/140723 Applicant SICHUAN SWIFTBIO BIOTECHNOLOGY CO., LTD Inventor CAO, Xu
Provided are an anti-CD3 antibody and a use thereof. Specifically, the provided anti-CD3 antibody can specifically bind to human and monkey CD3 proteins, and has similar binding properties. In addition, the provided anti-CD3 antibody has excellent bioactivity on various human CD3E proteins (including hCD3E&D heterodimer, and the like), and has significantly improved safety. Also provided is a humanized anti-CD3 antibody. The humanized antibody has properties of low immunogenicity, high hydrophilicity, and high stability, and is suitable for drug development.
9.WO/2025/140265COMBINATION OF CHIMERIC ANTIGEN RECEPTOR AND DAP10 IN CELL THERAPY
WO 03.07.2025
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
Appl.No PCT/CN2024/142173 Applicant WUXI BIOLOGICS (SHANGHAI) CO., LTD. Inventor CUI, Qian
Provided are expression constructs encoding chimeric antigen receptor and DAP10 recombinant polypeptide, engineered immune cells, and methods of use thereof. Further provided are activation and expansion of cells for therapeutic uses, especially for chimeric antigen receptor-based immune cell immunotherapy.
10.WO/2025/139524RECOMBINANT CAT ALLERGEN, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF
WO 03.07.2025
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
Appl.No PCT/CN2024/134148 Applicant ZONHON BIOPHARMA INSTITUTE, INC. Inventor MA, Bruce Yong
Provided are a recombinant cat allergen, a pharmaceutical composition therefor, a preparation method therefor, and a use thereof. Compared with naturally extracted allergen products, the recombinant cat allergen has multiple advantages in desensitization immunotherapy and allergen diagnosis for cat allergic diseases. For example, high purity and high uniformity are achieved; a pure protein/peptide having specified properties and quality is defined; the allergenicity, immunogenicity, and tolerability of the allergen are predetermined; production is performed according to GMP standards; the production of a specified quantity and concentration in a reproducible manner is enabled; product standardization and quality controllability are achieved; regulatory requirements for modern pharmaceuticals and vaccines are met; and when used for diagnosis, the allergen can identify allergen molecules that truly cause allergic reactions and reveal cross-reactivity, and when used for treatment, the allergen enables targeted allergen immunotherapy for a patient, avoiding the influence of non-allergenic substances in an extract, improving the safety, and facilitating precise diagnosis, precise administration, etc.